How to buy Synaptogenix (SNPX) stock

Synaptogenix, Inc. Common Stock is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Synaptogenix employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

Synaptogenix stock price (NASDAQ: SNPX)

Use our graph to track the performance of SNPX stocks over time.

Synaptogenix shares at a glance

• Key figures

Information last updated 2021-07-23.

52-week range	$0.65 - $14.40
50-day moving average	$9.36
200-day moving average	$8.68
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Synaptogenix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Synaptogenix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Synaptogenix, Inc. Common Stock by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synaptogenix financials

Gross profit TTM	$0
Return on assets TTM	-56.58%
Return on equity TTM	-112.63%
Profit margin	0%
Book value	$4.39
Market capitalisation	$72.5 million

TTM: trailing 12 months

Shorting Synaptogenix shares

There are currently 549,729 Synaptogenix shares held short by investors – that's known as Synaptogenix's "short interest". This figure is 456.6% up from 98,763 last month.

There are a few different ways that this level of interest in shorting Synaptogenix shares can be evaluated.

Synaptogenix's "short interest ratio" (SIR)

Synaptogenix's "short interest ratio" (SIR) is the quantity of Synaptogenix shares currently shorted divided by the average quantity of Synaptogenix shares traded daily (recently around 872585.71428571). Synaptogenix's SIR currently stands at 0.63. In other words for every 100,000 Synaptogenix shares traded daily on the market, roughly 630 shares are currently held short.

However Synaptogenix's short interest can also be evaluated against the total number of Synaptogenix shares, or, against the total number of tradable Synaptogenix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synaptogenix's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Synaptogenix shares in existence, roughly 100 shares are currently held short) or 0.2026% of the tradable shares (for every 100,000 tradable Synaptogenix shares, roughly 203 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synaptogenix.

Find out more about how you can short Synaptogenix stock.

Synaptogenix share dividends

We're not expecting Synaptogenix to pay a dividend over the next 12 months.

Synaptogenix overview

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York. .

Frequently asked questions

What percentage of Synaptogenix is owned by insiders or institutions?
Currently 31.443% of Synaptogenix shares are held by insiders and 12.186% by institutions. How many people work for Synaptogenix?
Latest data suggests 4 work at Synaptogenix. When does the fiscal year end for Synaptogenix?
Synaptogenix's fiscal year ends in December. Where is Synaptogenix based?
Synaptogenix's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036